尽管IBRX股价在资金和收益方面升, 但面临FDA警告以及证券集体诉讼. IBRX stock rose on funding and earnings, but faces FDA warnings and a securities class action lawsuit.

免疫生物 (IBRX) 的股价周二上,因为该公司获得了7500万美元的非稀释性融资并报告出比预期更好的收益. Shares of ImmunityBio (IBRX) rose Tuesday after the company secured $75 million in non-dilutive financing and reported better-than-expected earnings. 美国食品和药物管理局警告该公司未经证实的癌症治疗声明. However, the stock faces scrutiny after the FDA warned the company about unsupported cancer-treatment claims. 投资者可以在5月26日之前加入一项证券集体诉讼, Investors have until May 26 to join a securities class action lawsuit alleging the company made false statements about its product.